Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sweden's Medivir Strengthens Executive Team, Aims To Become Profitable Specialty Firm

This article was originally published in The Pink Sheet Daily

Executive Summary

With its hepatitis C protease inhibitor progressing in Phase III, Medivir starts to transform itself into a profitable specialty pharmaceutical company.
Advertisement

Related Content

People In The News: Tracking The Latest Industry Personnel Moves
People In The News: Tracking The Latest Industry Personnel Moves
Vertex Takes Early Lead In HCV Protease Inhibitor Sales
J&J's TMC435 Joins The Pharmasset Club
J&J's TMC435 Joins The Pharmasset Club
Hepatitis C Marketing: Applying Primary Care Tactics To Specialty Products
Medivir To Acquire BioPhausia's Commercial Platform To Market HCV Drug

Topics

Advertisement
UsernamePublicRestriction

Register

PS072753

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel